Excited to see the major financing news today from Halda Therapeutics. The company is trailblazing the development of the novel #RIPTAC modality for the treatment of #cancer, which offer the promise of overcoming treatment #resistance and addressing unmet needs in this field. Congratulations to our own Tim Shannon who serves as the company’s executive chair.
Today we announce a new financing of $126 million to advance RIPTAC™ therapeutics into the clinic. Six premier new investors join our syndicate: Deep Track Capital, Frazier Life Sciences, RA Capital Management, Vida Ventures, LLC, and Taiho Ventures. They join our strong foundation of existing investors: Canaan, Access Industries, Elm Street Ventures, and Connecticut Innovations. #RIPTACtherapeutics #HoldandKillCancer #CancerResearch https://lnkd.in/eQYsgXxC